[go: up one dir, main page]

EE200000486A - Fosfolipaasensüümide inhibiitorid, neid sisaldav farmatseutiline kompositsioon ning meetod põletikulise reaktsiooni raviks imetajal - Google Patents

Fosfolipaasensüümide inhibiitorid, neid sisaldav farmatseutiline kompositsioon ning meetod põletikulise reaktsiooni raviks imetajal

Info

Publication number
EE200000486A
EE200000486A EEP200000486A EEP200000486A EE200000486A EE 200000486 A EE200000486 A EE 200000486A EE P200000486 A EEP200000486 A EE P200000486A EE P200000486 A EEP200000486 A EE P200000486A EE 200000486 A EE200000486 A EE 200000486A
Authority
EE
Estonia
Prior art keywords
mammal
treating
pharmaceutical composition
composition containing
inflammatory response
Prior art date
Application number
EEP200000486A
Other languages
English (en)
Inventor
S. Seehra Jasbir
Kaila Neelu
C. Mckew John
Lovering Frank
E. Bemis Jean
Xiang Yibin
Original Assignee
Genetics Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute, Inc. filed Critical Genetics Institute, Inc.
Publication of EE200000486A publication Critical patent/EE200000486A/et

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200000486A 1998-02-25 1999-02-24 Fosfolipaasensüümide inhibiitorid, neid sisaldav farmatseutiline kompositsioon ning meetod põletikulise reaktsiooni raviks imetajal EE200000486A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3006298A 1998-02-25 1998-02-25
PCT/US1999/003899 WO1999043651A2 (en) 1998-02-25 1999-02-24 Inhibitors of phospholipase enzymes

Publications (1)

Publication Number Publication Date
EE200000486A true EE200000486A (et) 2002-02-15

Family

ID=21852314

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000486A EE200000486A (et) 1998-02-25 1999-02-24 Fosfolipaasensüümide inhibiitorid, neid sisaldav farmatseutiline kompositsioon ning meetod põletikulise reaktsiooni raviks imetajal

Country Status (19)

Country Link
EP (1) EP1056719A2 (et)
JP (1) JP2002504539A (et)
KR (1) KR20010041343A (et)
CN (1) CN1299347A (et)
AU (1) AU2782699A (et)
BG (1) BG104780A (et)
BR (1) BR9908280A (et)
CA (1) CA2322161A1 (et)
EA (1) EA200000868A1 (et)
EE (1) EE200000486A (et)
HR (1) HRP20000552A2 (et)
HU (1) HUP0100757A3 (et)
ID (1) ID27280A (et)
IL (1) IL137718A0 (et)
NO (1) NO20004220L (et)
PL (1) PL342995A1 (et)
SK (1) SK12742000A3 (et)
TR (1) TR200002446T2 (et)
WO (1) WO1999043651A2 (et)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000068223A1 (en) * 1999-05-05 2000-11-16 Aventis Pharma Limited Ureas and their use as cell adhesion modulators
AU7705601A (en) 2000-07-25 2002-02-05 Merck & Co Inc N-substituted indoles useful in the treatment of diabetes
AU2002243692B2 (en) 2001-01-29 2006-06-08 3-Dimensional Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
US6900218B2 (en) 2001-05-03 2005-05-31 Galileo Pharmaceuticals, Inc. Pyruvate derivatives
US6608196B2 (en) 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
US7291639B2 (en) 2001-06-20 2007-11-06 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
WO2003000253A1 (en) 2001-06-20 2003-01-03 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7189751B2 (en) * 2001-06-25 2007-03-13 Nippon Soda Co., Ltd. Oxa(thia)zolidine compounds, process for preparation thereof and anti-inflammatory agents
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
US6797708B2 (en) 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
EP1451154B1 (en) * 2001-12-03 2008-01-16 Wyeth Inhibitors of cytosolic phospholipase a2
US7101875B2 (en) 2001-12-03 2006-09-05 Wyeth Methods for treating arthritic disorders
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
SI1451154T1 (sl) * 2001-12-03 2008-06-30 Wyeth Corp Zaviralci citosolne fosfolipaze a2
US6984735B2 (en) 2001-12-03 2006-01-10 Wyeth Process for making an aldehyde
US6635771B2 (en) 2001-12-03 2003-10-21 Wyeth N-benzhydryl indole compounds
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
HRP20050181A2 (en) 2002-08-29 2006-03-31 Merck & Co. Inc. Indoles having anti-diabetic activity
US7393960B2 (en) 2002-08-29 2008-07-01 Merck & Co., Inc. Indoles having anti-diabetic activity
HRP20050396A2 (en) 2002-11-07 2005-06-30 Akzo Nobel N.V. Indoles useful in the treatment of androgen-receptor related diseases
US7078429B2 (en) 2002-12-10 2006-07-18 Wyeth Substituted 3-carbonyl-1H-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
ATE331708T1 (de) 2002-12-10 2006-07-15 Wyeth Corp Substituierte 3-alkyl- und 3-arylalkyl-1h-indol-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor-1 (pai-1) inhibitoren
MXPA05006283A (es) 2002-12-10 2005-08-19 Wyeth Corp Derivados de arilo, ariloxi, y alquiloxi del acido sustituido 1h-indol-3-il glicoxilico como inhibidores del inhibidor-1 activador de plasminogeno (pai-1).
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
BR0316584A (pt) 2002-12-10 2005-10-04 Wyeth Corp Derivados de ácido acético indol oxo-acetil amino substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
TW200510305A (en) * 2003-07-25 2005-03-16 Wyeth Corp Process for the preparation of CPLA2 inhibitors
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
TW200602317A (en) 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens
WO2005123673A1 (en) 2004-06-18 2005-12-29 Biolipox Ab Indoles useful in the treatment of inflammation
AU2005277139A1 (en) 2004-08-23 2006-03-02 Wyeth Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1
AU2005277137A1 (en) 2004-08-23 2006-03-02 Wyeth Pyrrolo-naphthyl acids as PAI-1 inhibitors
JP2008510815A (ja) 2004-08-23 2008-04-10 ワイス 血栓症および心臓血管疾患の治療にて有用な調節剤であるプラスミノゲン活性化因子阻害剤1型(pai−1)としてのオキサゾロ−ナフチル酸
RU2394027C2 (ru) * 2004-10-27 2010-07-10 Ф. Хоффманн-Ля Рош Аг Новые индольные или бензимидазольные производные
KR20070114123A (ko) * 2005-01-19 2007-11-29 바이올리폭스 에이비 염증 치료에 유용한 인돌
WO2007024294A2 (en) 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
TW200718687A (en) 2005-05-27 2007-05-16 Wyeth Corp Inhibitors of cytosolic phospholipase A2
CA2617372A1 (en) 2005-08-17 2007-02-22 Wyeth Substituted indoles and use thereof
EP2240444A1 (en) 2008-01-22 2010-10-20 Oxagen Limited Compounds having crth2 antagonist activity
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
EP2448938B9 (en) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinones as pi3k inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
EP2655374B1 (en) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
PL3513793T3 (pl) 2011-09-02 2021-09-20 Incyte Holdings Corporation Heterocykloaminy jako inhibitory pi3k
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
ES2657912T3 (es) 2012-07-17 2018-03-07 Glaxosmithkline Intellectual Property (No. 2) Limited Indolcarbonitrilos como moduladores selectivos de los receptores de andrógenos
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
RS63963B1 (sr) 2015-02-27 2023-03-31 Incyte Holdings Corp Postupak pripreme pi3k inhibitora
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
AU2019277560B2 (en) 2018-06-01 2025-04-24 Incyte Corporation Dosing regimen for the treatment of PI3K related disorders
TWI833819B (zh) 2018-10-05 2024-03-01 美商安尼波那生物公司 用於治療與apj受體活性相關的病狀的化合物及組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE314373B (et) * 1966-04-12 1969-09-08 Sumitomo Chemical Co
FR1492929A (fr) * 1966-05-11 1967-08-25 Roussel Uclaf Nouveaux 1-(omega-carboxyalcoyl) indoles substitués et procédé de préparation
US3505354A (en) * 1967-05-18 1970-04-07 Geigy Chem Corp 2-methyl-3-p-halobenzoylindole-n-aliphatic acids
DE1816335A1 (de) * 1968-12-21 1970-07-09 Thiemann Gmbh Chem Pharm Fabri Verfahren zur Herstellung von [2-Methyl-5-alkoxy-3-acyl-indol-1]-essigsaeuren und deren Estern
US4894386A (en) * 1987-04-15 1990-01-16 Ici Americas Inc. Aliphatic carboxamides
ES2045420T3 (es) * 1988-04-13 1994-01-16 Ici America Inc Amidas ciclicas.
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5290798A (en) * 1991-09-30 1994-03-01 Merck Frosst Canada, Inc. (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
NZ249729A (en) * 1992-05-13 1996-12-20 Syntex Inc Substituted indoles and azaindoles, preparation and pharmaceutical compositions thereof
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
DE4338770A1 (de) * 1993-11-12 1995-05-18 Matthias Dr Lehr Indol-2-alkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶
JP2000515529A (ja) * 1996-08-01 2000-11-21 メルクル・ゲーエムベーハー 細胞質ホスホリパーゼa▲下2▼の阻害剤としてのアシルピロリドンジカルボン酸およびアシルインドールジカルボン酸ならびにその誘導体
CA2264020A1 (en) * 1996-08-26 1998-03-05 Jean Bemis Inhibitors of phospholipase enzymes

Also Published As

Publication number Publication date
KR20010041343A (ko) 2001-05-15
SK12742000A3 (sk) 2001-05-10
WO1999043651A2 (en) 1999-09-02
AU2782699A (en) 1999-09-15
BR9908280A (pt) 2000-10-31
NO20004220D0 (no) 2000-08-23
EP1056719A2 (en) 2000-12-06
CN1299347A (zh) 2001-06-13
BG104780A (en) 2001-10-31
NO20004220L (no) 2000-10-05
PL342995A1 (en) 2001-07-16
HUP0100757A1 (hu) 2001-08-28
IL137718A0 (en) 2001-10-31
ID27280A (id) 2001-03-22
CA2322161A1 (en) 1999-09-02
EA200000868A1 (ru) 2001-04-23
TR200002446T2 (tr) 2000-12-21
HUP0100757A3 (en) 2001-11-28
WO1999043651A3 (en) 1999-12-16
JP2002504539A (ja) 2002-02-12
HRP20000552A2 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
EE200000486A (et) Fosfolipaasensüümide inhibiitorid, neid sisaldav farmatseutiline kompositsioon ning meetod põletikulise reaktsiooni raviks imetajal
BR0001422B1 (pt) aparelho e mÉtodo de reproduÇço.
EE200000522A (et) Fosfolipaas A2 ensüümi inhibiitor, seda sisaldav farmatseutiline kompositsioon ning meetod fosfolipaasensüümi toime pärssimiseks
NO20003096D0 (no) Sammensetninger og fremgangsmÕter for behandling av ADD
AU2001270054A1 (en) Method and system for determining personal characteristics of an individual or group
FI20021484A7 (fi) Rahapelijärjestelmä ja pelimenetelmä
DK199901519A (da) I form af små molekyler foreliggende inhibitorer af rotamase-enzymaktivitet
DE69904079D1 (de) Kombinationen von ileumgallensäuretransports inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
FI965019A7 (fi) Entsyymi-inhibiittoreita
NO20006700D0 (no) Innretning og fremgangsmåte for laserbelegging
EE9700182A (et) Mikrosoomse triglütseriidi transportproteiini inhibiitorid ja meetod
NO20004219L (no) Inhibitorer av fosfolipaseenzymer
NO991247L (no) Prosjektil og framgangsmaate for aa tilvirke et slikt
FI971801L (fi) Parannettu ääniviestijärjestelmä ja menetelmä sen käyttämiseksi
DE69912179D1 (de) Plattenwiedergabegerät und Verfahren
ID28025A (id) Metode pembuatan aminonitril dan diamina
DE69932573D1 (de) Wiedergabeverfahren und Wiedergabegerät
DK1098894T3 (da) FKBP-inhibitorer
NO20015318D0 (no) Metode for signering og autentisering av meldinger
NO995564D0 (no) Fremgangsmåte og konstruksjon for inhibisjon av cellemigrering
FI960534L (fi) Menetelmä analyyttien ei-kilpailevaa määritystä varten
NO20002436D0 (no) Sammensetning og fremgangsmÕte for fjerning av fosfationinnholdet i vann
FI981029A0 (fi) Menetelmä ja järjestely testaukseen
FI962282L (fi) Järjestely ja menetelmä soittamiseksi
DK1115389T3 (da) Fructosamin-oxidase: antagonister og inhibitorer